05:32 AM EDT, 09/29/2025 (MT Newswires) -- RAPT Therapeutics ( RAPT ) said Monday the US Food and Drug Administration cleared its investigational new drug application to begin a phase 2b study of RPT904 for food allergies.

The randomized, double-blind, placebo-controlled trial will test under-skin dosing every 8 or 12 weeks with an initial higher dose to evaluate safety and efficacy, the company said.

The study will enroll about 100 patients with at least one allergy, which will include milk, eggs, or nuts, RAPT said.